Show simple item record

dc.creatorOtero Patiño, Rafael
dc.creatorLeón Montero, Guillermo
dc.creatorGutiérrez, José María
dc.creatorRojas Céspedes, Gustavo
dc.creatorToro, María Fabiola
dc.creatorBarona, Jacqueline
dc.creatorRodríguez, Verónica
dc.creatorDíaz, Abel
dc.creatorNúñez Rangel, Vitelbina
dc.creatorQuintana, Juan Carlos
dc.creatorAyala, Shirley
dc.creatorMosquera, Diana Carolina
dc.creatorConrado, Lesdy L.
dc.creatorFernández, Diego
dc.creatorArroyo, Yobana
dc.creatorPiniagua, Carlos A.
dc.creatorLópez, Mercedes
dc.creatorOspina, Carlos E.
dc.creatorAlzate, Claudia
dc.creatorFernández, Jorge
dc.creatorMeza, Jazmín J.
dc.creatorSilva, Juan F.
dc.creatorRamírez, Patricia
dc.creatorFabra, Patricia E.
dc.creatorRamírez, Eugenio
dc.creatorCórdoba, Elkin
dc.creatorArrieta, Ana Berta
dc.creatorWarrell, David A.
dc.creatorTheakston, R. David G.
dc.date.accessioned2016-12-12T20:37:09Z
dc.date.available2016-12-12T20:37:09Z
dc.date.issued2006-12
dc.identifier.citationhttp://trstmh.oxfordjournals.org/content/100/12/1173es_ES
dc.identifier.issn1878-3503
dc.identifier.urihttp://hdl.handle.net/10669/29390
dc.description.abstractThe efficacy and safety of two whole IgG polyvalent antivenoms (A and B) were compared in a randomised, blinded clinical trial in 67 patients systemically envenomed by Bothrops asper in Colombia. Both antivenoms were fractionated by caprylic acid precipitation and had similar neutralising potencies, protein concentrations and aggregate contents. Antivenom B was additionally treated with β-propiolactone to lower its anticomplementary activity. Analysing all treatment regimens together, there were no significant differences between the two antivenoms (A = 34 patients; B = 33 patients) in the time taken to reverse venom-induced bleeding and coagulopathy, to restore physiological fibrinogen concentrations and to clear serum venom antigenaemia. Blood coagulability was restored within 6–24 h in 97% of patients, all of whom had normal coagulation and plasma fibrinogen levels 48 h after the start of antivenom treatment. Two patients (3.0%) had recurrent coagulopathy and eight patients suffered recurrence of antigenaemia within 72 h of treatment. None of the dosage regimens of either antivenom used guaranteed resolution of venom-induced coagulopathy within 6 h, nor did they prevent recurrences. A further dose of antivenom at 6 h also did not guarantee resolution of coagulopathy within 12–24 h in all patients. The incidence of early adverse reactions (all mild) was similar for both antivenoms (15% and 24%; P > 0.05).es_ES
dc.description.sponsorshipInstituto Colombiano para el Desarrollo de la Ciencia y la Tecnología Francisco José de Caldas//COLCIENCIAS/Colombiaes_ES
dc.description.sponsorshipUniversidad de Antioquia/[206PI0281]/CYTED/Colombiaes_ES
dc.description.sponsorshipUniversidad de Costa Rica//UCR/Costa Ricaes_ES
dc.language.isoen_USes_ES
dc.sourceTransactions of the Royal Society of Tropical Medicine and Hygiene; Volumen 100, Número 12. 2006es_ES
dc.subjectBothrops Asperes_ES
dc.subjectEnvenomationes_ES
dc.subjectSerotherapyes_ES
dc.subjectCaprylic acides_ES
dc.subjectβ-Propiolactonees_ES
dc.subjectAnticomplementary Activityes_ES
dc.subjectColombiaes_ES
dc.titleEfficacy and safety of two whole IgG polyvalent antivenoms, refined by caprylic acid fractionation with or without β-propiolactone, in the treatment of Bothrops asper bites in Colombiaes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.typeArtículo científicoes_ES
dc.identifier.doi10.1016/j.trstmh.2006.01.006
dc.description.procedenceUCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto Clodomiro Picado (ICP)es_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record